@article{ref1,
title="Levodopa-carbidopa-entacapone overdose presenting as altered mental status, xanthoderma, and yellowish sclera",
journal="Signa Vitae",
year="2018",
author="Lee, S.H. and Yun, S.J. and Ryu, S. and Choi, S.W. and Kim, H.J. and Kang, T.K. and Oh, S.C. and Cho, S.J.",
volume="14",
number="2",
pages="75-77",
abstract="Levodopa-carbidopa-entacapone is a single combination drug consisting of levodopa (aromatic amino acid), carbidopa (dopa-decarboxylase inhibitor), and entacapone (catechol-O-methyltransferase inhibitor). The Food and Drug Administration approved levodopa-carbidopaentacapone in 2003, as treatment for idiopathic Parkinson's disease in patients experiencing signs and symptoms of wearing-off. Although various adverse drug reactions of levodopa-carbidopa-entacapone have been recorded, there has been no reported case of levodopa-carbidopa-entacapone overdose. We report the first case of signs and symptoms of an overdose of levodopa-carbidopa-entacapone (levodopa: 3000 mg; carbidopa: 750 mg; entacapone: 6000 mg) in a suicide attempt, presenting as altered mentality, xanthoderma, and yellowish sclera without hyperbilirubinemia. © 2018, Pharmamed Mado Ltd. All rights reserved.<p /><p>Language: en</p>",
language="en",
issn="1334-5605",
doi="10.22514/SV142.102018.12",
url="http://dx.doi.org/10.22514/SV142.102018.12"
}